Your browser doesn't support javascript.
loading
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
Rosenwald, Andreas; Bens, Susanne; Advani, Ranjana; Barrans, Sharon; Copie-Bergman, Christiane; Elsensohn, Mad-Helenie; Natkunam, Yaso; Calaminici, Maria; Sander, Birgitta; Baia, Maryse; Smith, Alexandra; Painter, Daniel; Pham, Luu; Zhao, Shuchun; Ziepert, Marita; Jordanova, Ekaterina S; Molina, Thierry J; Kersten, Marie José; Kimby, Eva; Klapper, Wolfram; Raemaekers, John; Schmitz, Norbert; Jardin, Fabrice; Stevens, Wendy B C; Hoster, Eva; Hagenbeek, Anton; Gribben, John G; Siebert, Reiner; Gascoyne, Randy D; Scott, David W; Gaulard, Philippe; Salles, Gilles; Burton, Catherine; de Jong, Daphne; Sehn, Laurie H; Maucort-Boulch, Delphine.
Afiliación
  • Rosenwald A; University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
  • Bens S; Ulm University and Ulm University Medical Center, Ulm, Germany.
  • Advani R; Stanford Cancer Institute, Stanford, CA.
  • Barrans S; St James's University Hospital, Leeds, UK.
  • Copie-Bergman C; Université Paris-Est, Créteil, France.
  • Elsensohn MH; Hospices Civils de Lyon and Université de Lyon, Lyon, France.
  • Natkunam Y; Université Lyon 1, Villeurbanne, France.
  • Calaminici M; Stanford University School of Medicine, Stanford, CA.
  • Sander B; Queen Mary University of London, London, United Kingdom.
  • Baia M; Karolinska Institutet, Stockholm, Sweden.
  • Smith A; Karolinska University Hospital, Stockholm, Sweden.
  • Painter D; Université Paris-Est, Créteil, France.
  • Pham L; University of York, York, United Kingdom.
  • Zhao S; University of York, York, United Kingdom.
  • Ziepert M; Stanford Cancer Institute, Stanford, CA.
  • Jordanova ES; Stanford University School of Medicine, Stanford, CA.
  • Molina TJ; University of Leipzig, Leipzig, Germany.
  • Kersten MJ; Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Kimby E; Université Paris Descartes, Paris, France.
  • Klapper W; Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Raemaekers J; University of Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam, the Netherlands.
  • Schmitz N; Karolinska Institutet, Stockholm, Sweden.
  • Jardin F; University of Kiel, Kiel, Germany.
  • Stevens WBC; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
  • Hoster E; University Hospital Muenster, Muenster, Germany.
  • Hagenbeek A; Rouen University, Rouen, France.
  • Gribben JG; Radboud University Medical Center, Nijmegen, the Netherlands.
  • Siebert R; Ludwig Maximilian University of Munich, Munich, Germany.
  • Gascoyne RD; Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Scott DW; University of Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam, the Netherlands.
  • Gaulard P; Queen Mary University of London, London, United Kingdom.
  • Salles G; Ulm University and Ulm University Medical Center, Ulm, Germany.
  • Burton C; BC Cancer, Vancouver, British Columbia, Canada.
  • de Jong D; BC Cancer, Vancouver, British Columbia, Canada.
  • Sehn LH; Université Paris-Est, Créteil, France.
  • Maucort-Boulch D; Lyon University Hospital, Lyon, France.
J Clin Oncol ; 37(35): 3359-3368, 2019 12 10.
Article en En | MEDLINE | ID: mdl-31498031
ABSTRACT

PURPOSE:

MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies. The impact of MYC-R on prognosis may be influenced by the MYC partner gene (immunoglobulin [IG] or a non-IG gene). We evaluated a large cohort of patients through the Lunenburg Lymphoma Biomarker Consortium to validate the prognostic significance of MYC-R (single-, double-, and triple-hit status) in DLBCL within the context of the MYC partner gene.

METHODS:

The study cohort included patients with histologically confirmed DLBCL morphology derived from large prospective trials and patient registries in Europe and North America who were uniformly treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy or the like. Fluorescence in situ hybridization for the MYC, BCL2, BCL6, and IG heavy and light chain loci was used, and results were correlated with clinical outcomes.

RESULTS:

A total of 5,117 patients were identified of whom 2,383 (47%) had biopsy material available to assess for MYC-R. MYC-R was present in 264 (11%) of 2,383 patients and was associated with a significantly shorter progression-free and overall survival, with a strong time-dependent effect within the first 24 months after diagnosis. The adverse prognostic impact of MYC-R was only evident in patients with a concurrent rearrangement of BCL2 and/or BCL6 and an IG partner (hazard ratio, 2.4; 95% CI, 1.6 to 3.6; P < .001).

CONCLUSION:

The negative prognostic impact of MYC-R in DLBCL is largely observed in patients with MYC double hit/triple-hit disease in which MYC is translocated to an IG partner, and this effect is restricted to the first 2 years after diagnosis. Our results suggest that diagnostic strategies should be adopted to identify this high-risk cohort, and risk-adjusted therapeutic approaches should be refined further.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Translocación Genética / Reordenamiento Génico / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Proteínas Proto-Oncogénicas c-myc / Linfoma de Células B Grandes Difuso Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Año: 2019 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Translocación Genética / Reordenamiento Génico / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Proteínas Proto-Oncogénicas c-myc / Linfoma de Células B Grandes Difuso Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Año: 2019 Tipo del documento: Article País de afiliación: Alemania